Unique Topical Treatment for UV-Induced Skin Cancer

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$119,962.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA103378-01
Agency Tracking Number:
CA103378
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
BIOMEDICAL DEVELOPMENT CORP, 500 SANDAU, STE 200, SAN ANTONIO, TX, 78216
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 BAKUL BHATT
 (210) 308-0636
 BDC@BIOEVCORP.COM
Business Contact
 GREGG SIEGEL
Phone: (210) 308-0636
Email: GSIEGEL@BIODEVCORP.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The goal of this project is to develop a polymer-based vehicle for the topical delivery of caffeine to inhibit UV-induced skin cancer. Despite increased use of sun screen, skin cancer rates continue to rise. Recently, caffeine has been shown to inhibit carcinogenesis in murine models of UV-induced skin tumor formation. The polymer-based delivery system described in this proposal seeks to improve the efficacy and convenience of topically applied caffeine for this application. To achieve this goal, the following Specific Aims will be pursued: Aim 1. Formulate a Polymer-based Topical Delivery System Containing Caffeine Aim 2. Evaluate the Effect of Caffeine Delivered from the Polymer-based Vehicle on Ultraviolet Light-induced Skin Cancer Using a Mouse Model.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government